Remarkably, neither of the lncRNA-driven AML subtypes was found to be highly concordant with any of the conventional clinical or genetic factors, although enrichment in CEBPA, NPM1, FLT3-ITD and TP53 mutation was noted for particular subtypes. This evidence concerns the gene FLT3 and acute myeloid leukemia.